

# Welcome to the ECMC Annual Network Meeting

May 23<sup>rd</sup> 2019



Jointly  
funded by:



**NIHR** | National Institute  
for Health Research



# Aims of the Experimental Cancer Medicine Network

**ECMC vision:** to build a truly collaborative, internationally competitive national network of early phase experimental cancer medicine centres, translating the most promising innovations from the academic and industry sectors into the cancer medicines of tomorrow



Delivering innovative treatment  
for people with cancer



Making the UK the place of  
choice to deliver trials



Building the capacity of the  
Network


# ECMC network strategy: four main areas of focus



# ECMC network strategy: four main areas of focus



# ECMC network strategy: four main areas of focus



# NEW DIRECTIONS IN IMMUNO-ONCOLOGY

EMERGING BIOLOGY FOR  
THERAPY AND STRATIFICATION



10 - 12 SEPTEMBER 2019  
BUSH HOUSE, KING'S COLLEGE LONDON

FIND OUT MORE AND REGISTER HERE:  
<https://cancercentresioconference.co.uk/programme/>

BRINGING TOGETHER RESEARCH AND CLINICAL COMMUNITIES WORKING AT THE  
CUTTING EDGE OF IMMUNE-ONCOLOGY INTERVENTIONS AND THEIR STRATIFIED  
APPLICATION.

A partnership between the Cancer Research UK KHP and Birmingham Centres and the  
ECMC immunotherapy theme




CANCER  
RESEARCH  
UK

KHP  
CENTRE



CANCER  
RESEARCH  
UK

BIRMINGHAM  
CENTRE



11<sup>th</sup> International ICAPS Conference on

# Cancer Prevention: Targeting Infection, Inflammation and the Immune System

9th-10th of September 2019

Charterhouse Square (QMUL), LONDON, UK




## SAVE THE DATE

*Topics will include: Targeting inflammation and cytokine pathways, Aspirin, H. pylori eradication, HPV, HBsAg and novel vaccines, Anti-retrovirals, Checkpoint inhibitors.*



Register your  
interest and  
receive updates

Jointly organised by: UKTCPN and ICAPS



**UK therapeutic**  
**cancer prevention network**

*collaborating to prevent cancer*

**ecmc**



# PHASE 10

where science becomes medicine

14 - 16 JULY 2019


**MANCHESTER UK**

Hilton, Deansgate Manchester

[mcr.manchester.ac.uk/conference](http://mcr.manchester.ac.uk/conference)



# ECMC network strategy: four main areas of focus




# EC Trial Finder –our new trial finder tool

**Purpose:** Helps to drive trial recruitment by easily matching patients to early phase clinical trials within the ECMC network

**Uniqueness:** The power of the Network is utilised to address known challenges with existing databases i.e. lack of visibility of early phase trials, information accuracy and up-to-dateness

**How:** Easy search using customised criteria. Recruitment site contact details published to allow user to quickly determine patient eligibility and slot availability. Monthly data update by Sites.



Visibility of clinical trials to allow easier patient referrals



Improved patient access to trials



Opportunity to drive faster trial recruitment

## Our success in 4 months



### USERS

199 Users

*67% Adult, 33% Paediatric*



### TRIAL TYPES

62 cancer types

*77% Solid, 23% Haematological*

*72% adult, 3% Paeds, 25% Both*



### CONTENT

522 Trial records

*+200 added since the launch*



### MOLECULAR STRATIFICATION

45% of the trials include stratification information



### MONTHLY UPDATES

On average >90% of Sites provide data update every month




### CONTACT DETAILS

92% of records include phone and or email address

# Building a framework that ensures every child in the UK has equitable access to novel treatments

## ECMC Regional Network Discussion Panels



### ECMC Regional Network Discussion Panel Benefits

#### For Children-

To increase consideration of children to early phase clinical trials

To understand why children do NOT enter clinical trials, when it appropriate to do so.

To show that patients, where appropriate, have been considered for early phase trials.

To highlight unmet needs for patients

To increase chances of biopsy at relapse

#### For Clinicians

Generate data regarding relapse in paediatric patients to inform key discussions

Change management of patients

Change referral practises


Enable clinicians to feel informed of options

Encourage a clinician more likely to consider early phase options


# ECMC network strategy: four main areas of focus



# ECMC Junior Investigator Network Group (JING)



# A collaborative approach to Complex Innovative Design (CID) trials and their delivery



## Identification of issue

There was a need for clarity around the perceived difficulties in running CID trials in the UK.

An opportunity for the ECMC network to engage with regulators on clarifying the steps needed to open more CID trials in the UK.

## Collaborative workshops

- **33 stakeholders** from ECMC community, patients, clinical trials units, the pharmaceutical industry, funding bodies and regulators
- Development of consensus recommendations paper led by ECMC Programme Office with input from all stakeholders

## Recommendations paper


- *Effective delivery of Complex Innovative Design (CID) cancer trials* -paper submitted for publication review
- **10 consensus recommendations** created and disseminated across the Network '*How the UK and ECMC network is ready for CID trials and delivery 2019*'

# ECMC network strategy: four main areas of focus





# ECMC PO Industry Engagement 2019



arCCell    astellas    BAYER    BCN Biosciences

Bristol-Myers Squibb    CCA Clinical Research  
TRIALS WITHOUT THE TRIBULATIONS    COVANCE  
SOLUTIONS MADE REAL®

Debiopharm Group®  
WE DEVELOP FOR PATIENTS    IMMUNOCORE  
targeting T cell receptors    IQVIA™

Lilly    Lunaphore  
technologies    MiNA  
Therapeutics

NOVARTIS    PAREXEL®  
YOUR JOURNEY. OUR MISSION.™    PPD

Roche    SANOFI    SERVIER

## Combinations Alliance

astex  
pharmaceuticals    AstraZeneca    Athenex    BeiGene    CLOVIS ONCOLOGY    MedImmune    Pfizer    Plexxikon    Verastem  
novel drugs targeting cancer stem cells

# ECMC Programme Office



Head  
(Aoife Regan)

Comms & Marketing  
RBC



Data Manager  
(Dom Capostagno)

Network Lead  
(Ilaria Mirabile)



Combinations Alliance  
(Lyndall Maclellan & Cathy McDowell)



Ops and delivery lead  
(Fiona Chennels)




CRUK Paediatric Lead  
(Sheona Scales)




Project Manager –  
Capabilities  
(Aga Wabik)



Trial Manager  
(Olivia Frank)



Sandwich Student  
(Lucy Lettin)



Programme Office  
Manager  
(Sharan Sandhu)



Project Manager – EC  
Trial finder & reporting  
(Siru Vertanan)



Project Manager –  
Workforce  
(Hannah Brown)



Project Officer  
(Caroline Huxley)



ECMC Paediatric  
Network Manager  
(Vacant)

Thank you for your contribution  
to the network this year